Sama Therapeutics
Elias Mouchlianitis is a neuroscientist with extensive experience in cognitive neuroscience, currently serving as a Senior Lecturer at the University of East London since June 2021. Elias has held scientific advisory roles at VITAEVR LIMITED and UNIT9, focusing on virtual reality cognitive assessment and studying brain signals in professional race drivers, respectively. Previous positions include Research Fellow at Brunel University London, Research Associate at the Institute of Psychiatry, and Senior Scientist at Cambridge Cognition Plc, where expertise in neuroimaging and cognitive function assessment was applied. Elias completed a PhD at the University of Cambridge, investigating brain asymmetries and has contributed to significant research on schizophrenia and neuroinflammation during a career at the Medical Research Council.
This person is not in any teams
This person is not in any offices
Sama Therapeutics
1 followers
Sama Therapeutics is a precision neuropsychiatry AI/ML platform that synthesizes and validates predictive biomarkers grounded in neural, physiological, multi-omics, natural language, and behavioral phenotypes. The company's agile SaaS platform, iMAGiNE™, analyzes the transdiagnostic efficacy of pharmaceutical and neurostimulation modalities through precision clinical trials, causal inference, preclinical translation, and generative AI trained on proprietary and open-science datasets. With an extraordinarily interdisciplinary team, Sama Therapeutics is advancing "software as medical device" for a range of indications, including cognitive, affective, interoceptive, and substance use disorders. We invite partners to join our mission unlocking brain health through integrative neurotechnology and proven “transprognostic” algorithms: https://brainclinics.com/tdbrain-challenge/ Please reach out to contact@sama.ac for more information and a live demo.